Vireo Growth (VREOF) Asset Writedowns and Impairment (2022 - 2026)
Vireo Growth (VREOF) reported Asset Writedowns and Impairment of $300000.0 for Q1 2026, down 25.0% on a YoY basis from $400000.0 in Q1 2025, and down 86.88% sequentially from $2.3 million in Q4 2025.
Vireo Growth (VREOF) Asset Writedowns and Impairment (2022 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 4 years of Asset Writedowns and Impairment data on file, last reported at $300000.0 in Q1 2026.
- For the quarter ending Q1 2026, Asset Writedowns and Impairment fell 25.0% year-over-year to $300000.0; the trailing twelve-month figure through Mar 2026 stood at $3.4 million (up 274.14% YoY), and the FY2025 full-year result was $2.6 million, up 784.35% from the prior year.
- Asset Writedowns and Impairment declined to $300000.0 in Q1 2026, from $2.3 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $5.3 million in Q1 2022 to a low of -$304000.0 in Q1 2024.
- A 4-year average of $965084.7 and a median of $393000.0 in 2024 frame the typical range for Asset Writedowns and Impairment.
- Peak annual rise in Asset Writedowns and Impairment reached 3518.72% in 2025, while the deepest fall reached 651.58% in 2025.
- Tracing VREOF's Asset Writedowns and Impairment over 4 years: stood at $1.1 million in 2022, then plunged by 94.36% to $63182.0 in 2024, then surged by 3518.72% to $2.3 million in 2025, then slumped by 86.88% to $300000.0 in 2026.
- Business Quant data shows VREOF's Asset Writedowns and Impairment at $300000.0 in Q1 2026, $2.3 million in Q4 2025, and $996485.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 300,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | 2.29 Mn |
| Dec 31, 2025 | 2.29 Mn |
| Sep 30, 2025 | 996,485.00 |
| Sep 30, 2025 | 996,485.00 |
| Jun 30, 2025 | -226,149.00 |
| Jun 30, 2025 | -226,149.00 |
| Mar 31, 2025 | 400,000.00 |
| Mar 31, 2025 | 400,000.00 |
| Dec 31, 2024 | 63,182.00 |
| Dec 31, 2024 | 63,182.00 |
| Sep 30, 2024 | 393,000.00 |
| Sep 30, 2024 | 393,000.00 |
| Jun 30, 2024 | 41,000.00 |
| Jun 30, 2024 | 41,000.00 |
| Mar 31, 2024 | -304,000.00 |
| Mar 31, 2024 | -304,000.00 |
| Dec 31, 2022 | 1.12 Mn |
| Dec 31, 2022 | 1.12 Mn |